Opioid rotation with extended-release opioids: Where should we begin?

International Journal of General Medicine

Volumn 5, Issue , 2012, Pages 11-17

  Nalamachu, Srinivas ^a  

^a Clinical Research   (United States)

Author keywords

Chronic pain; Extended release opioids; Opioid rotation

Indexed keywords

FENTANYL; HYDROCODONE; HYDROMORPHONE; LEVORPHANOL; METHADONE; MORPHINE; OPIATE; OXYCODONE; OXYMORPHONE; NARCOTIC ANALGESIC AGENT;

ARTICLE; CANCER PAIN; CHRONIC PAIN; CONSTIPATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SELECTIVITY; HEALTH CARE POLICY; HUMAN; NAUSEA; NEUROPATHIC PAIN; PAIN; PAIN ASSESSMENT; PATIENT CARE; PRESCRIPTION; SOMNOLENCE; VIGNETTE; BREAKTHROUGH PAIN; CLINICAL EFFECTIVENESS; DRUG CHOICE; DRUG CONTROL; DRUG USE; HEART ARRHYTHMIA; MANAGED CARE; MEDICAL DECISION MAKING; OPIOID ROTATION; PATIENT ASSESSMENT; PATIENT MONITORING; PATIENT SELECTION; PHARMACEUTICAL CARE; RESPIRATION DEPRESSION; TIME TO TREATMENT; WITHDRAWAL SYNDROME;

EID: 84857073794     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S24287     Document Type: Article

References (47)

1. Galer BS, Coyle N, Pasternak GW, Portenoy RK. Individual variability in the response to different opioids: report of five cases. Pain. 1992; 49(1):87-91.
2. Chou R, Fanciullo GJ, Fine PG, et al. Opioid treatment guidelines: clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.
3. Fine PG, Portenoy RK. Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing "best practices" for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage.2009;38(3):418-425.
4. Slatkin NE. Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opin. 2009; 25(9):2133-2150.
5. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer. 1999;86(9):1856-1866.
6. Pan L, Xu J, Yu R, Xu MM, Pan YX, Pasternak GW. Identification and characterization of six new alternatively spliced variants of the human mu opioid eceptor gene, Oprm. Neuroscience. 2005;133(1): 209-220.
7. Pasternak GW. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci. 2001;22(2):67-70.
8. Eckhardt K, Li S, Ammon S, Schänzle G, Mikus G, Eichelbaum M. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain. 1998;76(1-2):27-33.
9. Russell RD, Chang KJ. Alternated delta and mu receptor activation: a stratagem for limiting opioid tolerance. Pain. 1989;36(3):381-389.
10. Exalgo [package insert]. Hazelwood, MO: Mallinckrodt Inc, a Covidien company; 2010.
11. Embeda [package insert]. Bristol, TN: King Pharmaceuticals; 2009.
12. Oxycontin [package insert]. Stamford, CT: Purdue Pharma LP; 2010.
13. Avinza [package insert]. Bristol, TN: King Pharmaceuticals Inc; 2008.
14. Opana ER [package insert]. Chadds Ford, PA: Endo Pharmaceuticals Inc; 2008.
15. Kadian [package insert]. Morristown, NJ: Actavis Elizabeth LLC; 2010.
16. MS Contin [package insert]. Stamford, CT: Purdue Pharma LP; 2009.
17. Oramorph SR [package insert]. Newport, KY: Xanodyne Pharmaceuticals Inc; 2006.
18. Duragesic [package insert]. Raritan, NJ: PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals Inc; 2006.
19. Nucynta ER [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc; 2011.
20. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6(2):107-112.
21. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011; 305(13):1315-1321.
22. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010; 152(2):85-92.
23. Hale M, Khan A, Kutch M, Li S. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain. Curr Med Res Opin. 2010;26(6):1505-1518.
24. Palangio M, Northfelt DW, Portenoy RK, et al. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage.2002;23(5):355-368.
25. US Food and Drug Administration. Questions and answers about oral prescription acetaminophen products to be limited to 325 mg per dosage unit. Available from: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm239871.htm. Accessed October 7, 2011.
26. US Food and Drug Administration. Acetaminophen overdose and liver injury - background and options for reducing injury. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM164897.pdf. Accessed November 1, 2011.
27. Quang-Cantagrel ND, Wallace MS, Magnuson SK. Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review. Anesth Analg. 2000;90(4):933-937.
28. Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage. 2009;38(3):426-439.
29. Mahler DL, Forrest WH Jr. Relative analgesic potencies of morphine and hydromorphone in postoperative pain. Anesthesiology. 1975;42(5): 602-607.
30. Smith H, Fine P, Passik S. Opioid Risk Management: Tools and Tips. New York: Oxford University Press, Inc; 2009.
31. Parsells Kelly J, Cook SF, Kaufman DW, Anderson T, Rosenberg L, Mitchell AA. Prevalence and characteristics of opioid use in the US adult population. Pain. 2008;138(3):507-513.
32. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7): 613-624.
33. Cone EJ, Darwin WD, Gorodetzky CW, Tan T. Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog. Drug Metab Dispos. 1978;6(4):488-493.
34. Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther. 1993;54(5): 463-472.
35. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004; 32(4):447-454.
36. Manchikanti L, Singh V, Caraway DL, Benyamin RM. Breakthrough pain in chronic non-cancer pain: fact, fiction, or abuse. Pain Physician. 2011;14(2):E103-E117.
37. Portenoy RK, Bennett DS, Rauck R, et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain. 2006;7(8):583-591.
38. Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics. J Opioid Manag. 2010;6(2): 97-108.
39. US Food and Drug Administration. Information for healthcare professionals: methadone hydrochloride. Rockville, MD: US Food and Drug Administration; 2006.
40. Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer.1996;78(4):852-857.
41. Davis AM, Inturrisi CE. d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. J Pharmacol Exp Ther. 1999;289(2):1048-1053.
42. Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. NCHS Data Brief. 2009;(22):1-8.
43. Savage SR, Joranson DE, Covington EC, Schnoll SH, Heit HA, Gilson AM. Definitions related to the medical use of opioids: evolution towards universal agreement. J Pain Symptom Manage. 2003;26(1): 655-667.
44. Gilson AM, Joranson DE, Maurer MA. Improving state pain policies: recent progress and continuing opportunities. CA Cancer J Clin. 2007; 57(6):341-353.
45. US Food and Drug Administration. Post-approval REMS notification letter. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM251595.pdf. Accessed July 29, 2011.
46. US Food and Drug Administration. Disposal of unused medicines: what you should know. Available from: http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/EnsuringSafeUseofMedicine/SafeDisposalofMedicines/ucm186187.htm. Accessed September 12, 2011.
47. US Food and Drug Administration. Questions and answers: FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for longacting and extended-release opioids. Available from: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm251752.htm. Accessed July 29, 2011.